IndustryCompany release

Cencora reports record fiscal 2026 revenue of $337.4bn and raises dividend by 10%

🇺🇸 Cencora, Inc. (COR) · Wed 04 Nov 2026

The wholesaler's full-year sales rose 5.0%, helped by the OneOncology acquisition, while it guides fiscal 2027 adjusted diluted EPS to $19.40-$19.75.

Cencora (NYSE: COR) announced on 4 November 2026 that revenue for the fourth quarter of fiscal 2026 reached $88.4 billion, an increase of 5.5%. Full-year revenue came to $337.4 billion, up 5.0%.

The company said growth was supported by its acquisition of OneOncology, completed in February 2026. This was partly offset by sales of GLP-1 products, which it described as lower-margin.

For fiscal 2027, Cencora guided adjusted diluted earnings per share to a range of $19.40 to $19.75. It also introduced new reportable segments, changing how it presents its results, and raised its quarterly dividend by 10%.

The summary available does not include further detail on segment definitions, profit figures or the size of the new dividend, so this report is limited to the headline figures.

What it means for your team

  • The OneOncology deal added to growth, a sign of continued consolidation in oncology distribution and services that market-access teams may want to track.
  • Lower-margin GLP-1 volumes weighed on the mix, which may be relevant to teams planning supply and pricing for that class.
  • The new reportable segments will change how Cencora's results are presented, so analysts comparing against earlier periods should check restated figures once available.

Company's press release (SEC filing): Cencora, Inc. ↗

Article written by VigiEye from the official source (Cencora, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →